Pitolisant in Refractory Restless Legs Syndrome

Phase 4 Unknown 18 enrolled William Ondo, MD Harmony Biosciences Management, Inc. · collab

NaSingle-groupOpen-labelTreatment

Summary

This is an open-label trial in Restless Legs Syndrome (RLS) patients inadequately treated with standard therapy, defined by an IRLS score greater than 15. Investigators hypothesize that the study drug, Pitolisant (Wakix), may improve RLS symptoms.

Timeline

Start: 2022-09-20
Primary completion: 2023-05-01
Completion: 2023-05-01

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Pitolisant	Small molecule	35.6 mg	—

Pitolisant in Refractory Restless Legs Syndrome

Summary

Timeline

Drugs

Indications